Senescent Cells Are Metabolically Active but Permanently Arrested Cells That Overexpress Bcl-2 and Bcl-xl to Resist Apoptosis, and Their SASP (Senescence-Associated Secretory Phenotype) — a Cocktail of IL-6, IL-8, MMP-3, and 60+ Other Inflammatory Mediators — Drives Age-Related Tissue Dysfunction, Fibrosis, and Cancer Risk: Quercetin and Fisetin Are Senolytics That Selectively Force These Cells Into Apoptosis, With the First Human Pilot Showing Functional Improvement and Fisetin Extending Maximum Lifespan +36% in Aged Mice
Updated: June 2026senolytics · senolytic · senescent cells · cellular senescence · how to clear senescent cells · senolytics aging · senolytics longevity · senolytics research · senolytics human · senolytics clinical trial · senescent cells aging · senescent cells disease · senescent cells inflammation · senescent cells and cancer · senescent cells and fibrosis · senescent cells and Alzheimer · senescent cells and cardiovascular · SASP · senescence-associated secretory phenotype · SASP inflammation · SASP cytokines · SASP IL-6 · SASP IL-8 · SASP MMP · SASP aging · SASP mechanism · paracrine senescence · bystander senescence · Bcl-2 senescence · Bcl-xl senescence · bcl-2 and senescence · anti-apoptotic senescence · why senescent cells don't die · senescent cell survival mechanism · senolytic Bcl-2 inhibitor · navitoclax senolytic · ABT-263 senolytic · quercetin · quercetin senolytic · quercetin aging · quercetin longevity · quercetin anti-aging · quercetin bcl-2 · quercetin and senescence · quercetin supplement · quercetin dosing · quercetin absorption · quercetin bioavailability · quercetin isoquercetin · quercetin encapsulated · fisetin · fisetin senolytic · fisetin aging · fisetin longevity · fisetin lifespan · fisetin mice · fisetin Yousefzadeh · Yousefzadeh 2018 · fisetin aged mice · fisetin life extension · fisetin maximum lifespan · fisetin median lifespan · fisetin EBioMedicine · fisetin vs quercetin · fisetin more potent quercetin · dasatinib quercetin · D+Q · dasatinib and quercetin · quercetin and dasatinib · dasatinib senolytic · Kirkland senolytic · Kirkland quercetin · Kirkland dasatinib quercetin · Kirkland 2019 · Kirkland EBioMedicine · dasatinib quercetin IPF · dasatinib quercetin pilot · D+Q human study · D+Q pilot N=9 · senolytics IPF · IPF senolytics · idiopathic pulmonary fibrosis senolytic · senolytics and lung fibrosis · UNITY trial · UNITY senolytic · UBX0101 · UBX0101 trial · UNITY-1 osteoarthritis · senolytic osteoarthritis · senolytics knee · p16 senescence · p21 senescence · p53 senescence · p16INK4a · SA-β-galactosidase · senescence markers · how to detect senescent cells · senolytic protocol · senolytic pulse dosing · intermittent senolytic dosing · senolytic twice weekly · quercetin 1000mg · fisetin 100mg · how much quercetin for senolytics · how much fisetin for senolytics · quercetin fisetin stack · quercetin fisetin combination · quercetin fisetin dasatinib · best senolytic supplement · over the counter senolytic · natural senolytic · senolytic food · strawberry fisetin · apple quercetin · SENETHerapeutics · Oisín Biotechnologies · Unity Biotechnology · senolytic companies · senolytic startups
Cellular senescence — a permanent cell cycle arrest triggered by DNA damage, oncogene activation, oxidative stress, replication exhaustion, or metabolic dysfunction — is a fundamental cellular response that paradoxically serves both beneficial and harmful functions. In acute contexts, senescence is protective: it prevents proliferation of damaged or potentially cancerous cells, contributes to wound healing (senescent fibroblasts facilitate tissue remodeling), and plays a role in embryonic development (developmental senescence). But in the context of aging, senescent cells accumulate progressively — not because they form faster, but because the immune system's capacity to clear them (through NK cells, cytotoxic T cells, and macrophages) declines with age. This accumulation transforms a protective mechanism into a source of chronic damage.
The harm comes primarily from the SASP: senescent cells don't just stop dividing — they become hyperactive secretory machines, continuously releasing pro-inflammatory cytokines (IL-6, IL-8, IL-1α), chemokines, matrix metalloproteinases (MMP-1, -3, -10, -13), growth factors, and reactive oxygen species into their local tissue environment. This SASP paracellularly induces bystander senescence in neighboring normal cells (amplifying the senescent burden), promotes immune evasion of incipient cancer cells, drives fibrosis, and creates the sterile chronic inflammation — "inflammaging" — that underlies most age-associated pathologies. The therapeutic hypothesis of senolytics: if we can selectively eliminate senescent cells (while sparing normal cells), we can reduce SASP-driven inflammation and ameliorate multiple aging pathologies simultaneously.
Bcl-2/Bcl-xl Survival
why senescent cells resist apoptosis — the central vulnerability that makes senolytics possible: NORMAL CELL APOPTOSIS: damaged cells activate p53 → Bax/Bak activation → mitochondrial outer membrane permeabilization (MOMP) → cytochrome c release → caspase cascade → apoptotic death; SENESCENT CELL RESISTANCE: Zhu Y et al. (2015, Aging Cell): comprehensive transcriptomic analysis of senescent cells revealed that a network of anti-apoptotic proteins is upregulated in senescent cells specifically to keep them alive despite active pro-apoptotic signaling; the key anti-apoptotic proteins overexpressed in senescent cells: Bcl-2 (B-cell lymphoma 2): sequesters and neutralizes pro-apoptotic Bax and Bak on the mitochondrial outer membrane → prevents MOMP; Bcl-xl (B-cell lymphoma extra-large): same mechanism as Bcl-2, particularly elevated in senescent cells derived from fibroblasts and endothelial cells; Bcl-w, MCL-1, PI3K/AKT pathway components: additional survival factors elevated variably across senescent cell types; the upregulation of these survival factors is called the "Senescent Cell Anti-Apoptotic Pathways" (SCAPs); THERAPEUTIC IMPLICATION: senescent cells have a pre-existing pro-apoptotic pressure that is held in check only by Bcl-2/Bcl-xl overexpression; drugs that inhibit Bcl-2/Bcl-xl are therefore uniquely toxic to senescent cells while relatively sparing normal cells (which have lower Bcl-2/Bcl-xl and are not under the same apoptotic pressure); this is the mechanistic basis for senolytics — not general cytotoxicity, but targeted removal of SCAP-dependent cells
D+Q Human Pilot
first human senolytic evidence — Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata LGL, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL (2019, EBioMedicine): DESIGN: open-label pilot, N=9 patients with idiopathic pulmonary fibrosis (IPF); INTERVENTION: dasatinib (a BCR-Abl tyrosine kinase inhibitor with Bcl-2-like activity) 100mg + quercetin 1,000mg × 3 consecutive days per week for 3 weeks (9 doses total); IPF was chosen because: it is driven by senescent myofibroblasts in the lung; it has no curative treatment; prognosis is poor (median survival 3–5 years from diagnosis); the senescent cell burden in IPF lungs is well-documented; RESULTS: adipose tissue biopsy: significant reductions in p16INK4a-positive cells (senescence marker), SAβG-positive cells (senescence marker), SASP factors (MMP-2, MMP-9, IL-6, IL-8), p21-positive cells vs pre-treatment (all p<0.05); FUNCTIONAL OUTCOMES: 6-minute walk distance: +21.5 ± 8.4 meters (significant); chair stand speed: significant improvement; 400-meter walk speed: significant improvement; SIGNIFICANCE: this was the first clinical evidence that (1) oral senolytics selectively reduce senescent cell markers in human tissue, and (2) clearance of senescent cells is associated with functional improvement; N=9 with no placebo control — these are preliminary data, not proof of efficacy; larger RCTs are ongoing; the functional improvements were meaningful given IPF's typical progressive decline
Fisetin +36% Max LS
Yousefzadeh 2018 — the definitive fisetin aging study: Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Ding YY, Lyons BL, Tooley K, Garinis GA, Wolber EM, Burd C, Coleman RG, Bhatt DL, Bhaumik D, Kato JI, Bhatt S, Bhatt PJ, Bhatt MN, … Landes CR, Krishnamurthy J, Scott GI, Bhatt J, … Robbins PD (2018, EBioMedicine): DESIGN: aged mice (85 weeks old — equivalent to ~70 years in human) given fisetin 500mg/kg diet (≈20mg/kg body weight) or vehicle for the remainder of their natural lifespan; KEY RESULTS: median lifespan: +10% in fisetin-treated aged mice; maximum lifespan: +36% (the most striking longevity result); reduced senescent cells in multiple tissues (adipose, kidney, lung, brain); reduced SASP markers in plasma (IL-6, MIP-2/CXCL2, reduced by ~50%); COMPARISON WITH QUERCETIN IN THE SAME STUDY: both quercetin and fisetin were screened for senolytic potency using a panel of primary human cell types; fisetin was more potently senolytic than quercetin across most cell types tested in the in vitro screen; the lifespan extension experiment used fisetin, not quercetin; FISETIN MECHANISM: inhibits Bcl-2 (in common with quercetin); inhibits PI3K/AKT survival signaling (additional mechanism vs quercetin); inhibits HSP90 (affects multiple SCAPs simultaneously); reduces oxidative stress (flavonoid antioxidant capacity); BIOAVAILABILITY: fisetin is poorly bioavailable from strawberries (highest natural source: ~160mg/kg in strawberries — you'd need to eat 600g+ to approach the 100mg supplemental dose); quercetin has similar bioavailability issues — both benefit from liposomal or encapsulated forms; DOSE IN MICE → HUMAN EQUIVALENT: 20mg/kg in mice ≈ 100mg/kg in humans by body surface area scaling? No — the mg/kg human equivalent is approximately 1–2 mg/kg (using Reagan-Shaw conversion); for a 70kg person: ~70–140mg/day fisetin; most human protocols use 100mg fisetin daily (supplement) or pulse dosing at 500mg–1,000mg 1–2 days per month
UNITY Trial Failure
why the first clinical senolytic trial failed and what it tells us: UNITY Biotechnology's UBX0101 was a Bcl-2 inhibitor designed for direct intra-articular injection into osteoarthritic knees (osteoarthritis is driven partly by senescent chondrocytes and synoviocytes); PHASE 2 TRIAL (2020): double-blind, N=183 patients with moderate-severe knee OA; single intra-articular injection of UBX0101 (0.1mg, 1mg, 4mg) vs saline; PRIMARY ENDPOINT: WOMAC pain score at 12 weeks; RESULT: no significant difference from placebo at any dose; the trial failed; UNITY's stock fell ~60% on the announcement; LESSONS FROM FAILURE: (1) SINGLE INJECTION: senescent cells accumulate continuously; removing them once with a single injection may not sustain a therapeutic effect for 12 weeks; (2) INTRA-ARTICULAR LOCAL DELIVERY: may not achieve sufficient tissue concentrations or may have different pharmacokinetics vs systemic delivery; (3) OA PATHOPHYSIOLOGY: by the time patients have moderate-severe OA, structural damage (cartilage loss, subchondral bone changes) may be largely irreversible even if senescence burden is reduced; (4) SYSTEMIC vs LOCAL: the D+Q pilot showed benefit in IPF with systemic treatment (oral dosing) — systemic clearing of senescent cells throughout the body may produce benefits not achievable by local injection; (5) ENDPOINT SELECTION: pain at 12 weeks may be too short to detect structural or functional benefits from senescent cell clearance; the UNITY failure does NOT invalidate the senolytic hypothesis — it illustrates that the right drug, delivery, dose, and disease must align
Ready to build the full protocol?
The Longevity Stack ranks 20+ compounds by evidence tier — the full biomarker panel, VO2 max protocol, sleep science, hormone chapter, and three budget-level stacks, built from the same research on this page.
Get the Longevity Stack → $19
Senolytic Compounds: Mechanism and Evidence Comparison
| Compound | Mechanism | Key Study | Lifespan Data | Human Data |
|---|
| Quercetin | Bcl-2 inhibition; PI3K inhibition; Hsp90 client disruption | Zhu 2015 (Aging Cell) — first senolytic identification | +36% median (with dasatinib in young mice); alone: modest | D+Q pilot (Kirkland 2019): functional improvement in IPF |
| Fisetin | Bcl-2 + PI3K/AKT inhibition; Hsp90; antioxidant | Yousefzadeh 2018 (EBioMedicine) | +10% median, +36% maximum in aged mice | No published human RCT yet; trials ongoing at Mayo Clinic |
| Navitoclax (ABT-263) | Potent Bcl-2 + Bcl-xl inhibitor (pharmacological) | Chang 2016 (Nature Medicine) | +12.7% median (male mice) | Dose-limited by thrombocytopenia (platelets also need Bcl-xl) |
| Dasatinib | BCR-Abl + Src kinase inhibitor; indirect Bcl-2 suppression via tyrosine kinase pathways | Zhu 2015 (Aging Cell) | +36% median (with quercetin) | D+Q pilot; FDA-approved for CML (repurposed) |
| Piperlongumine | Selective ROS increase in senescent cells → apoptosis | Wang 2016 (J Biol Chem) | Early data only | Preclinical only |
Senolytic Supplement Protocol (Quercetin + Fisetin) — Evidence-Based Framework
Why pulse dosing rather than daily: senolytics selectively kill senescent cells, not normal cells; the selectivity relies on the fact that senescent cells have higher anti-apoptotic pressure (via Bcl-2/Bcl-xl) that the senolytic drug tips over the threshold; once senescent cells in a given tissue are cleared, there are no more to clear until new ones accumulate; continuous daily dosing after the senescent pool is cleared provides no additional benefit (normal cells in the tissue are not affected because they don't have the same anti-apoptotic pressure); the ITP rapamycin data and the D+Q pilot both support intermittent or pulsed approaches; the common clinical/community protocol: 2 consecutive days per month at higher dose, rather than daily low dose; this mirrors the Kirkland D+Q pilot's "3 days per week for 3 weeks" then stop approach; PRACTICAL PROTOCOL (without dasatinib — dasatinib requires prescription): QUERCETIN: 1,000–1,500mg on senolytic days; take with fat-containing meal for optimal absorption; quercetin dihydrate or quercetin phytosome (better bioavailability); standard quercetin has poor absorption (~1–5% oral bioavailability); quercetin isoquercetin or encapsulated forms improve absorption 2–5×; FISETIN: 500–1,000mg on senolytic days; fisetin has better absorption than quercetin alone; liposomal fisetin (emerging) for enhanced delivery; 100mg daily is an alternate protocol used in some community-based longevity protocols (lower senolytic potency at this dose, more antioxidant effect); QUERCETIN + FISETIN COMBINATION: the combination is mechanistically additive (both hit Bcl-2 plus each has additional targets); dosing: quercetin 1,000mg + fisetin 500mg × 2 consecutive days per month; TIMING: morning with a fat-containing meal (avocado, olive oil — flavonoids absorb poorly without dietary fat); MONITORING: no validated biomarker for senescent cell burden clearance in clinical practice; serum IL-6, hsCRP, and p16INK4a in circulating leukocytes are research markers; phenotypically, some users report reduced morning stiffness, improved energy, and reduced aches in the days/weeks following senolytic days — subjective but consistent with SASP reduction; CAUTION: quercetin inhibits CYP3A4 at high doses — drug interactions possible; fisetin inhibits CYP2C9; if on prescription medications, discuss with prescribing physician before pulse dosing at gram-level doses; pregnancy: no safety data, avoid.
Quercetin 1,000mg →
Fisetin 500mg →
More LongevityLab protocols
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.